How does 1XU's PB Ratio compare to its peers?

1XU is good value based on its Price-To-Book Ratio (4.3x) compared to the peer average (5.1x).

How does 1XU's PB Ratio compare vs other companies in the DE Biotechs Industry?

1XU is expensive based on its Price-To-Book Ratio (4.3x) compared to the European Biotechs industry average (2.4x).

What is 1XU's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 1XU's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of 1XU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate 1XU's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Entheon Biomedical (DB:1XU) - Stock Price, News & Analysis

1XU Stock Overview

Operates as a biotechnology research and development company. More details

1XU fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Earnings have grown 46.4% per year over the past 5 years

Risk Analysis

Does not have a meaningful market cap (€1M)

Makes less than USD$1m in revenue (CA$0)

Has less than 1 year of cash runway

Highly volatile share price over the past 3 months compared to the German market

+ 1 more risk

Entheon Biomedical Corp. Competitors

bioXXmed

XTRA:T5O

€1.4m

co.don

XTRA:CNW

€6.5m

Medigene

XTRA:MDG1

€22.5m

2invest

XTRA:2INV

€62.7m

Price History & Performance

Summary of all time highs, changes and price drops for Entheon Biomedical
Historical stock prices
Current Share Price	CA$0.085
52 Week High	CA$0.15
52 Week Low	CA$0.01
Beta	1.05
11 Month Change	21.43%
3 Month Change	30.77%
1 Year Change	18.06%
33 Year Change	-97.79%
5 Year Change	n/a
Change since IPO	-97.42%

Recent updates

Shareholder Returns

	1XU	DE Biotechs	DE Market
7D	-3.4%	-0.2%	0.8%
1Y	18.1%	-16.9%	9.1%

Return vs Industry: 1XU exceeded the German Biotechs industry which returned -17.2% over the past year.

Return vs Market: 1XU exceeded the German Market which returned 8.5% over the past year.

Price Volatility

Is 1XU's price volatile compared to industry and market?
1XU volatility
1XU Average Weekly Movement	19.0%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 1XU's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 1XU's weekly volatility has decreased from 74% to 19% over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
n/a	1	Timothy Ko	www.entheonbiomedical.com

Entheon Biomedical Corp. operates as a biotechnology research and development company. It engages in developing of products for treating addiction and substance use disorders. The company is headquartered in Vancouver, Canada.

Entheon Biomedical Corp. Fundamentals Summary

How do Entheon Biomedical's earnings and revenue compare to its market cap?
1XU fundamental statistics
Market cap	€784.83k
Earnings (TTM)	-€209.68k
Revenue (TTM)	n/a

0.0x

P/S Ratio

-3.2x

P/E Ratio

Is 1XU overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1XU income statement (TTM)
Revenue	CA$0
Cost of Revenue	CA$0
Gross Profit	CA$0
Other Expenses	CA$307.69k
Earnings	-CA$307.69k

Last Reported Earnings

Aug 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.035
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 1XU perform over the long term?

See historical performance and comparison

1XU Stock Overview

Rewards

Risk Analysis

Entheon Biomedical Corp. Competitors

XTRA:T5O

€1.4m

XTRA:CNW

€6.5m

XTRA:MDG1

€22.5m

XTRA:2INV

€62.7m

Price History & Performance

Recent News & Updates

Entheon Biomedical Corp., Annual General Meeting, Dec 16, 2024

First quarter 2024 earnings released: CA$0.013 loss per share (vs CA$0.016 loss in 1Q 2023)

New minor risk - Shareholder dilution

Entheon Biomedical Corp. announced that it has received CAD 0.1475 million in funding

Entheon Biomedical Corp. announced that it expects to receive CAD 0.1475 million in funding

Full year 2023 earnings released: CA$0.051 loss per share (vs CA$0.35 loss in FY 2022)

Recent updates

Entheon Biomedical Corp., Annual General Meeting, Dec 16, 2024

First quarter 2024 earnings released: CA$0.013 loss per share (vs CA$0.016 loss in 1Q 2023)

New minor risk - Shareholder dilution

Entheon Biomedical Corp. announced that it has received CAD 0.1475 million in funding

Entheon Biomedical Corp. announced that it expects to receive CAD 0.1475 million in funding

Full year 2023 earnings released: CA$0.051 loss per share (vs CA$0.35 loss in FY 2022)

Entheon Biomedical Corp., Annual General Meeting, Dec 29, 2023

New major risk - Financial position

Entheon Biomedical Corp. Announces Termination of Andrew Hegle as Chief Science Officer

First quarter 2023 earnings released: CA$0.002 loss per share (vs CA$0.032 loss in 1Q 2022)

Entheon Biomedical Corp., Annual General Meeting, Apr 19, 2023

Entheon Biomedical Corp. Announces CFO Changes

High number of new and inexperienced directors

Entheon Biomedical Corp. Closes Patient Enrolment in its Clinical Research Study EBIQ-101

High number of new and inexperienced directors

Entheon Biomedical Corp. announced that it expects to receive CAD 3 million in funding

Entheon Biomedical Corp. Announces EBIQ-101 First-Patient Dose

Entheon Biomedical Corp. Announces the Approval of DMT Clinical Trial

Entheon Biomedical Corp. Announces the Submission of the Regulatory Package for Its Upcoming Phase 1 Clinical Trial

High number of new and inexperienced directors

Entheon Biomedical Provides Update on Clinical and Preclinical DMT Programs

Entheon Biomedical Corp. Announces Sponsorship of a Clinical Study to Assess the Electroneurophysiologic Effects of Ketamine

New 90-day low: €0.45

Entheon Biomedical Corp. Announces Nancy Maher as Special Advisor of Data Science and Regulatory Affairs

Entheon Biomedical Announces Ethics Approval for in Vivo DMT Study

Entheon Biomedical Corp. Appoints Dr. Brian Jahns to the Role of Chief Business Officer

Entheon Biomedical Corp. to Be Included in First North American Psychedelic ETF

Entheon Biomedical Partners with Divergence Neuro Technologies Inc. for Predictive Biomarker Platform Development

Entheon Biomedical Corp. (CNSX:ENBI) acquired HaluGen Life Sciences Inc. for CAD 4.2 million.

Entheon Biomedical Corp. announced that it has received CAD 3.214515 million in funding

Entheon Biomedical Corp. announced that it has received CAD 3.174374 million in funding

Entheon Biomedical Announces Dmt Drug Supply Agreement with Psygen Labs Inc. Completion of Initial Dmt Research Drug Batch and Exercise of Warrants

Shareholder Returns

Price Volatility

About the Company

Entheon Biomedical Corp. Fundamentals Summary

0.0x

-3.2x

Earnings & Revenue